{"id":8651,"date":"2025-09-18T00:32:58","date_gmt":"2025-09-17T21:32:58","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=8651"},"modified":"2025-09-18T00:32:58","modified_gmt":"2025-09-17T21:32:58","slug":"this-week-in-cardiology-highlights","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/this-week-in-cardiology-highlights\/","title":{"rendered":"This Week in Cardiology \u2013 Highlights"},"content":{"rendered":"
This Week in Cardiology \u2013 Highlights<\/div>\n
<\/div>\n
Source:\u00a0 Medscape \u2013 Podcast.<\/div>\n
Date: September 12, 2025 :<\/div>\n
<\/div>\n
1. Beta-Blockers (DANBLOCK\/REBOOT)<\/span><\/div>\n
\u2022 Benefit seen in LVEF 40\u201349% (\u224825% relative risk reduction).<\/span><\/div>\n
\u2022 Still cheap, safe, and supported by evidence.<\/span><\/div>\n
2. ESC 2025 Valvular Guidelines<\/span><\/div>\n
\u2022 CCTA before valve surgery = Class I, B (but weak evidence).<\/span><\/div>\n
\u2022 Asymptomatic severe AS: early TAVR Class IIa (bias concerns).<\/span><\/div>\n
\u2022 TAVR in younger patients: long-term durability uncertain.<\/span><\/div>\n
\u2022 TEER in TR: Class IIa, risk of overuse.<\/span><\/div>\n
\u2022 Surgical AF ablation: evidence weak, guidelines oversimplify.<\/span><\/div>\n
3. Baxdrostat (Resistant HTN)<\/span><\/div>\n
\u2022 \u2193 SBP by ~15 mmHg vs ~6 mmHg placebo.<\/span><\/div>\n
\u2022 Hyperkalemia noted; few patients on spironolactone.<\/span><\/div>\n
\u2022 Comment : Nearly no patients on spironolactone; unclear added value vs cheap MRAs.<\/span><\/div>\n
\u2022 May be promising, but not \u201cgame changing.\u201d<\/span><\/div>\n
4. Myosin Inhibitors in HCM<\/span><\/div>\n
\u2022 Obstructive HCM (MAPLE): aficamten improved VO\u2082, NYHA, LVOT, BNP.<\/span><\/div>\n
\u2022 Non-obstructive HCM (ODYSSEY): no benefit; strong placebo effect.<\/span><\/div>\n
\u2022 Effective only in obstructive HCM; cost and long-term safety remain concerns.<\/span><\/div>\n
5. Vericiguat<\/span><\/div>\n
\u2022 VICTOR trial: no significant benefit in ambulatory HFrEF.<\/span><\/div>\n
\u2022 Meta-analysis (VICTOR + VICTORIA): small effect (HR 0.91).<\/span><\/div>\n
\u2022 No meaningful role beyond 4 pillars of GDMT.<\/span><\/div>\n
6. Digoxin (RATE AF substudy)<\/span><\/div>\n
\u2022 In AF (mean age 75): digoxin improved EF, lowered NT-proBNP, fewer adverse events than \u03b2-blockers.<\/span><\/div>\n
\u2022 May be as good or better than \u03b2-blockers for rate control in AF + HFpEF.<\/span><\/div>\n
<\/div>\n
Takeaway:<\/div>\n
\u2022 Old drugs (BBs, digoxin) still matter.<\/span><\/div>\n
\u2022 New drugs (baxdrostat, myosin inhibitors, vericiguat) interesting but need caution.<\/span><\/div>\n
\u2022 ESC 2025 guidelines criticized for overstating weak evidence.<\/span><\/div>\n
<\/div>\n
https:\/\/www.medscape.com\/viewarticle\/1002909<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

This Week in Cardiology \u2013 Highlights Source:\u00a0 Medscape \u2013 Podcast. Date: September 12, 2025 : 1. Beta-Blockers (DANBLOCK\/REBOOT) \u2022 Benefit seen in LVEF 40\u201349% (\u224825% relative risk reduction). \u2022 Still cheap, safe, and supported by evidence. 2. ESC 2025 Valvular Guidelines \u2022 CCTA before valve surgery = Class I, B (but weak evidence). \u2022 Asymptomatic […]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-8651","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8651","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=8651"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8651\/revisions"}],"predecessor-version":[{"id":8652,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8651\/revisions\/8652"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=8651"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=8651"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=8651"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}